Compare EXLS & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXLS | GRFS |
|---|---|---|
| Founded | 1999 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.2B |
| IPO Year | 2006 | 2006 |
| Metric | EXLS | GRFS |
|---|---|---|
| Price | $42.33 | $9.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $54.50 | $10.15 |
| AVG Volume (30 Days) | ★ 1.2M | 443.2K |
| Earning Date | 02-24-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.53% |
| EPS Growth | ★ 29.94 | N/A |
| EPS | ★ 1.48 | 0.64 |
| Revenue | $2,026,490,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | $15.32 | $5.36 |
| Revenue Next Year | $11.27 | $5.15 |
| P/E Ratio | $28.38 | ★ $18.34 |
| Revenue Growth | ★ 14.43 | 7.31 |
| 52 Week Low | $37.30 | $6.19 |
| 52 Week High | $52.43 | $11.14 |
| Indicator | EXLS | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 55.13 |
| Support Level | $40.71 | $9.04 |
| Resistance Level | $43.67 | $9.46 |
| Average True Range (ATR) | 0.72 | 0.21 |
| MACD | -0.15 | 0.02 |
| Stochastic Oscillator | 51.04 | 64.10 |
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.